MARLBOROUGH, Mass. (AP) — Sepracor Inc. said Friday that its insomnia drug Lunesta did not reach its main goal in a clinical trial that tested it as a treatment for generalized anxiety disorder. In mid stage testing involving 440 patients, the drug did not significantly reduce symptoms of generalized anxiety disorder. The symptoms were evaluated using a clinical survey. Sepracor said it is analyzing data from the trial to see if the drug reached any secondary goals, and will decide if it will continue developing the drug. The trial tested a modified-release formation of eszopiclone, which is sold as the sleep aid Lunesta in the U.S. and Lunivia in Europe. GlaxoSmithKline PLC markets the drug outside of North America and Japan.